Research programme: Niemann-Pick disease therapeutics - Biovista/Wylder Nation Foundation

Drug Profile

Research programme: Niemann-Pick disease therapeutics - Biovista/Wylder Nation Foundation

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wylder Nation Foundation
  • Class
  • Mechanism of Action Sphingolipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Niemann-Pick disease type A

Most Recent Events

  • 24 Sep 2015 Biovista and Wylder Nation Foundation agree to co-develop in USA for Niemann-Pick disease type A
  • 02 Sep 2015 Early research in Niemann-Pick disease type A in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top